Proresid in the long-term treatment of rheumatoid arthritis.

Abstract

Drug withdrawal rate and reasons for treatment termination were studied in a retrospective life-table analysis of patients with rheumatoid arthritis prescribed Proresid, a semisynthetic podophyllotoxin derivative. Two years after starting with Proresid medication, half of the patients were still on treatment. After 5 years the termination rate had risen to 71%. Gastrointestinal side effects were the most common reason for abandoning medication. The results are compared with those found in other studies of similar desing. It is concluded that Proresid is a valuable and well-tolerated disease-modifying drug for long-term treatment of rheumatoid Arthritis.

• Authors: J Lysholm, T Weitoft
• Journal: Scandinavian journal of rheumatology (Scand J Rheumatol) Vol. 17 Issue 6 Pg. 465-8 ( 1988) ISSN: 0300-9742 [Print] England
• PMID: 3232037 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• mitopodozide
• Podophyllin
• Podophyllotoxin

Topics

• Actuarial Analysis
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Arthritis, Rheumatoid (drug therapy)
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Podophyllin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Podophyllotoxin (analogs & derivatives)
• Retrospective Studies